BCL2L1 is identified as a target of naringenin in regulating ovarian cancer progression.

Xu, Jing; Guo, Zhe; Yuan, Shuang; Li, Heli

Xu, Jing; Guo, Zhe; Yuan, Shuang; Li, Heli.

Affiliation

Xu J; Department of Obstetrics and Gynecology, Nanyang Central Hospital, No. 312 Gongnong Road, Nanyang, 473005, China. xjfkybq@163.com.
Guo Z; Department of Obstetrics and Gynecology, Nanyang Central Hospital, No. 312 Gongnong Road, Nanyang, 473005, China.
Yuan S; Department of Obstetrics and Gynecology, Nanyang Central Hospital, No. 312 Gongnong Road, Nanyang, 473005, China.
Li H; Department of Obstetrics and Gynecology, Nanyang Central Hospital, No. 312 Gongnong Road, Nanyang, 473005, China.

Mol Cell Biochem ; 477(5): 1541-1553, 2022 May.

Article de En | MEDLINE | ID: mdl-35184257

Sujet(s)
Mots clés

BCL2L1; Naringenin; Ovarian cancer; PI3K/Akt pathway

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs de l'ovaire / Protéines proto-oncogènes c-akt Type d'étude: Prognostic_studies Limites: Humans Langue: En Journal: Mol Cell Biochem Année: 2022 Type de document: Article Pays d'affiliation: Chine

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google